Phase 1 Clinical Trial: Carbapenem-resistant Enterbacterales (CRE)

NIH RePORTER · NIH · N01 · $2,320,888 · view on reporter.nih.gov ↗

Abstract

The Phase I Clinical Trial Units provide a vehicle for the investigation of new therapeutic and immunomodulatory agents for the treatment of infectious disease.

Key facts

NIH application ID: 10655939
Project number: 272201500005I-0-759302200057-2
Recipient: DYNPORT VACCINE COMPANY, LLC
Principal Investigator: GRAIG SHOCKEY
Activity code: N01
Funding institute: NIH
Fiscal year: 2022
Award amount: $2,320,888
Award type: —
Project period: 2021-12-14 → 2023-11-30